Study Investigates Non-Surgical Placement of a Gore-tex Type Device in the Heart to Stop Recurrent Strokes and Mini-StrokesNovember 19, 2008(CHICAGO) - A study is under way at Rush University Medical Center using a small, soft-patch device made of a Gore-tex-type material - often used to make durable outerwear - to close a common hole found in the heart called a patent foramen ovale (PFO) in order to prevent recurrent strokes and transient ischemic attacks (TIAs) in adults. Rush is the only academic medical center in the Chicago area involved in the trial and one of only 50 sites in the U.S. and the world. The randomized, multinational clinical research trial may determine if repairing a PFO using this device, also known as the GORE HELEX Septal Occluder, is more effective in preventing strokes than medical management alone. The U.S. Food and Drug Administration (FDA) recently granted approval to use the device for PFO closures. It is currently approved by the FDA for the treatment of atrial septal defects (ASDs), a congenital heart defect found in young children. "This PFO-closure device uses a biocompatible material that allows progressive tissue growth to help seal the defect," Dr. Ziyad Hijazi, director of the Rush Center for Congenital and Structural Heart Disease and co-investigator of the clinical trial at Rush. "It shows promise because of its soft, flexible design that has the ability to conform to a patient's anatomy." The miniature umbrella-like device is fed through a catheter that is placed in the vein of the patient's leg using just one small puncture. The catheter is led through the vein up to the heart where the device is placed to seal the flap. "Everyone is born with a PFO, which normally closes after birth "said Hijazi. "But in one in five Americans, the closure process is incomplete allowing blood returning from the body to bypass the filtering system of the lungs and enabling blood clots to travel from one area of the body through the heart and up to the brain causing a stroke." Most often, patients do not show any signs or symptoms, and a PFO can go undetected through adulthood. It is not until a patient experiences a stroke that a PFO defect is often diagnosed. Many of these strokes occur in people under the age of 50. "Stroke has many causes. Unfortunately, in approximately twenty-five percent of cases, we do not find a specific cause. It has been suggested that in these cases, which are referred to as cryptogenic stroke, PFO might be a potential risk factor," said Dr. Vivien Lee, stroke neurologist and study co-investigator at Rush. "The question we are trying to answer with this study is whether a PFO closure can reduce the risk of recurrent stroke." The purpose of the study is to help patients like Nathan Prince, a 31-year-old truck driver from Justice, Ill., who learned he had a congenital hole in his heart after suffering two strokes in three days. "I was completely shocked," said Prince. "I kept thinking I am way too young. I never experienced any symptoms. I am pretty athletic and always on the go. All of this seemed so sudden." Prince was immediately put on anticoagulants and other medication. "I was pretty upset when I found out that I had to take all this medication," said Prince. "I mean, I am a young guy and now I have to take all these medicines and who knows what the long term effects could be." Prince's neurologist referred him to Rush University Medical Center to see Hijazi. "When Dr. Hijazi explained to me that I could have a procedure that could close up that hole, stop my stroke symptoms and be home the next day, I immediately asked how soon we could do the procedure," said Prince. The same afternoon as his procedure, Nathan was up, reading, moving around and ready to go home. "I'm just happy that I won't have to be on all those medications anymore," said Prince. Currently, the primary treatment option is medical management. "This study may provide useful information that will help us determine a new possible standard of care for stroke patients," said Lee. "We have medications options that work well in reducing a stroke patient's risk of recurrence, but now we can see if PFO closure is an additional option that may also be beneficial to stroke patients. MRI-imaging will be performed on all patients as a baseline in order to make comparisons between treatment arms. To participate in the study, you must be 18-60-years-old, have a presence of a PFO with a history of cryptogenic stroke or imaging-confirmed TIA. To enroll in the study, contact Catherine Glase at 312-942-9398. ### Rush University Medical Center is an academic medical center that encompasses the more than 600 staffed-bed hospital (including Rush Children's Hospital), the Johnston R. Bowman Health Center and Rush University. Rush University, with more than 1,270 students, is home to one of the first medical schools in the Midwest, and one of the nation's top-ranked nursing colleges. Rush University also offers graduate programs in allied health and the basic sciences. Rush is noted for bringing together clinical care and research to address major health problems, including arthritis and orthopedic disorders, cancer, heart disease, mental illness, neurological disorders and diseases associated with aging. Rush University Medical Center |
|||||||||||||||||||||
| Related Stroke Current Events and Stroke News Articles Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study Researchers at St. Michael's Hospital working in conjunction with EMS services, paramedics and fire services across Ontario found that a bystander who attempts cardiopulmonary resuscitation (CPR) can quadruple the survival rate to over 50 per cent. Higher carotid arterial stenting rates associated with poorer clinical outcomes Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine. Study suggests dentists can identify patients at risk for fatal cardiovascular event A new study indicates dentists can play a potentially life-saving role in health care by identifying patients at risk of fatal heart attacks and referring them to physicians for further evaluation. Estrogen therapy likely must be given soon after menopause to provide stroke protection For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience. Researchers identify drug candidate for treating spinal muscular atrophy A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. Clinical tests begin on medication to correct Fragile X defect NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. Brain tumors in childhood leave a lasting mark on cognition, life status Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems. A decade later, lifestyle changes or metformin still lower type 2 diabetes risk Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent compared with placebo in people at high risk for the disease, researchers conclude based on 10 years of data. Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women. More Stroke Current Events and Stroke News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||